



MARKET RELEASE

27 November 2013

Cynata Therapeutics Limited

PRE-REINSTATEMENT DISCLOSURE

Cynata Therapeutics Limited (the "Company") will be reinstated to official quotation as from the commencement of trading on Friday, 29 November 2013, following the Company's compliance with listing rule 11.1.3 and chapters 1 and 2 of the ASX listing rules.

The following information is released as pre-reinstatement disclosure.

1. Appendix 1A and Information Form and Checklist.
2. Distribution schedule.
3. Top 20 holders.
4. A statement setting out the number of securities subject to escrow and the escrow period applied to those securities.
5. A statement setting out the capital structure of the Company.
6. An updated statement of financial position based on the actual amount of funds raised pursuant to the prospectus.
7. An updated statement of commitments based upon actual funds raised under the prospectus.
8. The full terms of the Company's options on issue.
9. A statement confirming that the Licensee Agreement with Wisconsin Alumni Research Foundation effective on 26 March 2013 remains in full force and effect.
10. A statement confirming satisfaction of the conditions precedent and completion of the Option Agreements between the Company and the vendors of Cynata dated 12 July 2013 ("Option Agreements") and the issue of 10,000,001 fully paid ordinary shares in the Company (on a post-consolidation basis) to the vendors of Cynata in accordance with the Options Agreements.
11. A statement confirming there have been no material subsequent events to alter the Company's statement of financial position as detailed on page 48 of the Prospectus.
12. A statement confirming the Company is in compliance with the listing rules and in particular listing rule 3.1.

Security Code: CYP
CYPO

Adam Russo
Adviser, Listings Compliance (Perth)

For personal use only